Founded by a team of world-class scientists returning to China who have been selected for the Chinese “National Thousand Talents Program”, Clover Biopharmaceuticals is passionate about developing transformative biologic therapies for the millions of Chinese patients who currently do not have access to modern biological medicines.?Seeking to Change the Paradigm in China |?Emerging only recently from the advent of modern biotechnology, biologics today represent the majority of the world’s most efficacious therapies due to their high target specificity and lower off-target toxicities compared to small molecule drugs. In fact, biologics generated over US$150 billion in global sales and represented over 70% of the combined sales from the top 10 drugs worldwide in 2015. However, few of these therapies are approved in China, and most Chinese people are not able to access them at affordable prices. Clover is seeking to change this paradigm.?Decades of Biologics Development & Manufacturing Expertise |?These biological drugs are highly-complex and require extensive technical expertise to develop and manufacture that most domestic Chinese companies do not have. Our leadership team has decades of experience in biologics development needed to successfully bring such therapies to market.??Developing Novel Biologics & Differentiated Biosimilars |?We are developing a robust portfolio of novel biologics and differentiated biosimilars to treat the world’s most debilitating diseases – autoimmune, cancer and infectious diseases. We are utilizing our proprietary Trimer-Tag? technology to develop novel, trimerized fusion-protein therapies.?Our primary focus is on the China market but plan to develop our therapies globally if they meet an unmet need for patients worldwide.?三葉草生物制藥是由一組世界頂級海外歸來的科學家創(chuàng)立，其核心團隊包括5位國家“千人計劃”入選者。我們熱衷于為數(shù)以百萬計無法獲得現(xiàn)代生物藥品的中國病患者研發(fā)革新性的生物靶向制藥。三葉草生物團隊獲得了2009年國務院僑辦頒發(fā)的 “重點華僑華人創(chuàng)業(yè)團隊”稱號，并入選2012年成都市首批團隊。公司創(chuàng)新性靶向生物制藥研發(fā)共獲得3項國家十二五“重大新藥創(chuàng)制”重大專項及“抗體藥物關鍵技術”863計劃的立項支持和認可， 并受到各級地方政府， 包括成都高新區(qū)、 成都市和四川省的重點扶持。尋求改變中國生物制藥現(xiàn)狀 |?隨著現(xiàn)代生物技術的問世，生物制藥雖在近期才逐漸興起卻已因其相比小分子藥物更高的專一性和較低的副作用成為了當今世界大多數(shù)有效的疾病治療手段。事實上, 生物制藥在**已擁有超過1500億美金的銷售額并占據(jù)了2015年世界銷售額排名前10名藥物的70%。但是，只有極少一部分生物制藥療法在中國獲得到了批準；就算是被批準的藥物，它們的價格對于絕大多數(shù)中國人來說也是望塵莫及，。三葉草生物致力于改變這個現(xiàn)狀。數(shù)十年的生物制藥研發(fā)與生產(chǎn)經(jīng)驗 |?生物制藥是一個極其復雜的系統(tǒng)工程、而且需要大量目前中國國內(nèi)企業(yè)所不具備的專業(yè)技術來研發(fā)和制造。我們的核心領導團隊具有數(shù)十年的生物制藥研發(fā)及產(chǎn)業(yè)化經(jīng)驗，將現(xiàn)代生物制藥成功地推向市場。創(chuàng)新性生物靶向藥物和革新性生物仿制藥 |?我們致力于用三葉草首創(chuàng)的“蛋白質(zhì)三聚體化”（Trimer-Tag? ）生物邏輯制藥平臺技術為支撐，以我們獨有的AP-TAG 技術為藥物高通量篩選技術手段，從事多種創(chuàng)新性的三聚融合蛋白靶向藥物、疫苗和革新性生物仿制藥的研發(fā)，用其治療世界上各種嚴重的疾病 – 包括自身免疫性疾病，癌癥和傳染性疾病。?中國市場是我們目前的首要焦點；但如果世界上其他地區(qū)有未滿足的對生物制藥的需求，我們將在**范圍內(nèi)研發(fā)和推廣我們的革新性生物制藥及療法。